Home  |  Archive  |  Online Submission  |  News & Events  |  Subscribe  |  APFA  |  Society  |  Links  |  Contact Us  |  中文版
Search   
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

Links

Meetings
Journals
Societies & Institutes
Hospitals
Databases & Libraries
Companies
Websites
Other links

 
Abstract

Volume 18, Issue 1 (January 2016) 18, 16–20; 10.4103/1008-682X.160270

Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results

Ravi Kacker, Hult Mariam, Ignacio F San Francisco, William P Conners, Pablo A Rojas, William C Dewolf, Morgentaler Abraham

Men's Health Boston, Brookline, MA, USA
Pontifical Catholic University of Chile, Santiago, Chile
Department of Urology, Beth Israel Deaconess Medical Center, Boston, MA, USA

Correspondence: Dr. R Kacker

21-Aug-2015

Abstract

This report presents our experience with T therapy in a cohort of T‑deficient men on active surveillance (AS) for Gleason 3 + 3 and
Gleason 3 + 4 prostate cancer (PCa). A retrospective chart review identified 28 men with T deficiency who underwent T therapy (T group)
for at least 6 months while on AS for PCa. A comparison group of 96 men on AS for PCa with untreated T deficiency (no‑T group) was
identified at the same institution. The AS protocol followed a modified Epstein criteria and allowed inclusion of men with a single core of low‑volume Gleason 3 + 4 PCa. Mean age was 59.5 and 61.3 years, and mean follow‑up was 38.9 and 42.4 months for the T and no‑T
groups, respectively. Of all 28 men in the T group, 3 (10.7%) men developed an increase in Gleason score while on AS. Of 22 men in
the T group with Gleason 3 + 3 disease, 7 (31.8%) men developed biopsy progression including 3 men (13.6%) who developed Gleason
3 + 4 PCa. Of 6 men with Gleason 3 + 4 disease at baseline, 2 (33.3%) men developed an increase in tumor volume, and none developed
upgrading beyond Gleason 3 + 4. All 96 men in the no‑T group had Gleason 3 + 3 disease at baseline and, 43 (44.7%) developed biopsy
progression, including 9 men (9.38%) with upgrading to Gleason 7 (3 + 4). Biopsy progression rates were similar for both groups and
historical controls. Biopsy progression in men on AS appears unaffected by T therapy over 3 years. Prospective placebo‑controlled trials of T therapy in T‑deficient men on AS should be considered given the symptomatic benefits experienced by treated men.

Full Text | PDF | 中文摘要 |

 
Browse:  507
 
Copyright 1999-2017  Shanghai Materia Medica, Shanghai Jiao Tong University.  All rights reserved